CA2981933A1 - Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique - Google Patents

Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique Download PDF

Info

Publication number
CA2981933A1
CA2981933A1 CA2981933A CA2981933A CA2981933A1 CA 2981933 A1 CA2981933 A1 CA 2981933A1 CA 2981933 A CA2981933 A CA 2981933A CA 2981933 A CA2981933 A CA 2981933A CA 2981933 A1 CA2981933 A1 CA 2981933A1
Authority
CA
Canada
Prior art keywords
compound
benzo
methyl
dioxido
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2981933A
Other languages
English (en)
French (fr)
Inventor
Marie Lamothe
Didier Junquero
Bruno Le Grand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CA2981933A1 publication Critical patent/CA2981933A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CA2981933A 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique Abandoned CA2981933A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1553574A FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
FR1553574 2015-04-21
PCT/EP2016/058760 WO2016169983A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Publications (1)

Publication Number Publication Date
CA2981933A1 true CA2981933A1 (fr) 2016-10-27

Family

ID=53484018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981933A Abandoned CA2981933A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Country Status (12)

Country Link
US (1) US20180140609A1 (enExample)
EP (1) EP3285774B1 (enExample)
JP (1) JP2018513175A (enExample)
KR (1) KR20170139030A (enExample)
CN (1) CN107530355A (enExample)
AU (1) AU2016251601A1 (enExample)
BR (1) BR112017021586A2 (enExample)
CA (1) CA2981933A1 (enExample)
FR (1) FR3035326B1 (enExample)
MX (1) MX2017013453A (enExample)
RU (1) RU2017137262A (enExample)
WO (1) WO2016169983A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177304B1 (ko) 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
RU2706026C1 (ru) * 2018-12-28 2019-11-13 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体
FR2942797B1 (fr) * 2009-03-03 2011-04-29 Pf Medicament Derives de benzothiazines, leur preparation et leur application a titre de medicaments
KR101134447B1 (ko) * 2009-11-30 2012-04-10 에스케이 주식회사 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
JP2011213685A (ja) * 2010-04-01 2011-10-27 Kowa Co ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
ES2543692T3 (es) * 2010-04-29 2015-08-21 The University Of Edinburgh (8-aza-biciclo[3.2.1biciclo[oct-8-il)-[5-(1H-pirazol-4-il)-tiofeno-3-il]-metanonas 3,3-disustituidas como inhibidores de 11beta-HSD1
ES2617215T3 (es) * 2011-04-19 2017-06-15 Daiichi Sankyo Company, Limited Derivado de tetrahirotiazepina

Also Published As

Publication number Publication date
FR3035326B1 (fr) 2017-05-12
EP3285774A1 (fr) 2018-02-28
WO2016169983A1 (fr) 2016-10-27
AU2016251601A1 (en) 2017-11-30
RU2017137262A3 (enExample) 2019-09-30
US20180140609A1 (en) 2018-05-24
KR20170139030A (ko) 2017-12-18
BR112017021586A2 (pt) 2018-07-03
CN107530355A (zh) 2018-01-02
FR3035326A1 (fr) 2016-10-28
EP3285774B1 (fr) 2020-01-08
JP2018513175A (ja) 2018-05-24
RU2017137262A (ru) 2019-05-21
MX2017013453A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
EP1675836B1 (fr) Derives du 4-phenylthiazole et leur utilisation comme medicaments pour le traitement de maladies neurodegeneratives, la douleur et l'epilepsie
EP2170349B1 (fr) Traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains par un antagoniste de l'aldostérone
JP6689078B2 (ja) 超高純度なテトラヒドロカンナビノール−１１−酸
EP1583538B1 (fr) Utilisation de la 3-methoxy-pregnenolone pour la préparation d'un médicament destiné à traiter les maladies neurodegeneratives
CZ289556B6 (cs) Dialkylethery obsahující koncové karboxyskupiny nebo tetrazolové skupiny a farmaceutická kompozice obsahující tyto dialkylethery jako účinnou látku
EP3285774B1 (fr) Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
FR2933609A1 (fr) Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
FR2849598A1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
CA3005527C (fr) Mirabegron pour le traitement de maladies retiniennes
WO2017178630A1 (fr) Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
EP2254567B1 (fr) N-acetyl-taurinate de zinc pour son utilisation dans une méthode de prévention et/ou de traitement des maladies avec accumulation de lipofuscine
JP2022505033A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
EP3897633A1 (fr) Utilisation d'un antagoniste de par-1 pour le traitement d'une maladie inflammatoire chronique intestinale
WO2016046457A1 (fr) Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines cytokines chimio-attractantes
EP2755649B1 (fr) Utilisation de la 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour la prevention et/ou le traitement des effets cardiotoxiques dus a la chimiotherapie et/ou les rayonnements
TW201102372A (en) Indane analogs and use as pharmaceutical agents and process of making
US20230346765A1 (en) Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof
FR2878522A1 (fr) Nouveaux inhibiteurs specifiques de la caspas-10
EP1257568B9 (fr) Derives de l'echinocandine, leur procede de preparation et leur application comme fongicides
FR2849599A1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
WO2014162106A1 (fr) Nouveaux derives de chalcone presentant une activite anti-allergique
WO2006090616A1 (ja) 脂肪細胞分化調節剤
EP2167078A2 (fr) Utilisation du pactimibe pour la préparation d'un médicament destiné à prévenir ou à traiter une maladie due à un dysfonctionnement des glandes sébacées chez l'homme ou l'animal
WO2009044006A2 (fr) L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301